TacticScaleWhat Solventum Does & How It Makes Money (SOLV)
Updated October 2026 · reflects Solventum's latest reported financials
Healthcare company making wound care, dental, and hospital software products. It earns revenue by selling medical, surgical, and dental products to healthcare providers through direct sales, distributors, key account management, inside sales, and e-commerce, and by licensing software solutions to health systems.
How Solventum makes money
It earns revenue by selling medical, surgical, and dental products to healthcare providers through direct sales, distributors, key account management, inside sales, and e-commerce, and by licensing software solutions to health systems.
What Solventum does
Solventum Corporation is a healthcare company, incorporated in 2023 and headquartered in Eagan, Minnesota, that operates through three segments. Its largest-scope Medsurg segment covers a wide range of hospital and clinical products, including negative pressure wound therapy, advanced wound dressings and skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes, stethoscopes, electrodes, and components for original equipment manufacturers. The Dental Solutions segment supplies orthodontic and dental products such as brackets, aligners, restorative cements, and bonding agents for preventive care, restoration, and orthodontics. The Health Information Systems segment provides software to health systems for physician documentation, coding automation and direct-to-bill, classification methodologies, speech recognition, and data visualization. Products reach customers through direct, distribution, key account, inside sales, and e-commerce channels in the U.S. and internationally.
Products & services
- Negative pressure wound therapy
- Advanced wound dressings
- Stethoscopes
- Orthodontic brackets and aligners
- Dental restorative cements and bonding agents
- Clinical documentation and coding automation software
What is Solventum worth?
On an owner-earnings DCF, Solventum's most-likely value is about $20 versus a recent price near $87 (77% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$13) with a margin of safety — so the honest verdict here is “Stretched — richly priced.” Fair value earns its keep only at the extremes, not in the wide middle.
Today's $87 is above even the optimistic Bull case ($29) — the market expects faster, longer growth than modeled here. Expensive unless that extra growth actually shows up.
⚠ High leverage — net debt is 27.8× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
⚠ Capital-intensive — this business reinvests heavily, so free cash flow runs well below its earnings. Fair value here is built on free cash flow, which understates owner earnings for reinvestment-heavy companies — read it as conservative.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Waters (WAT) · STERIS (STE) · Merit Medical Systems (MMSI) · DENTSPLY SIRONA (XRAY) · Integra LifeSciences (IART)